facebook button TAPISTRY: Multiple Cohort Solid Tumor Trial
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

TAPISTRY: Multiple Cohort Solid Tumor Trial

Sponsor: Hoffmann-La Roche

TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. For patients with specific qualifying mutations in any of the following genes: ROS1, NTRK1/2/3, ALK, AKT1/2/3, HER2, or PIK3CA.